Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HGS CEO hails from TAP

Executive Summary

Former TAP Pharmaceuticals President Thomas Watkins joins Human Genome Sciences as CEO. Watkins worked for Abbott-affiliated companies for almost 20 years, including six years serving as president of the Takeda/Abbott joint venture; his term as president was limited by the joint venture agreement (1"The Pink Sheet" Sept. 6, 2004, p. 8). Watkins replaces former HGS CEO William Haseltine, PhD, who also retired as chairman; Argeris Karabelis, PhD, became chairman Oct. 17...

You may also be interested in...

TAP President Will Be Former Sales VP Alan MacKenzie

Former TAP VP-sales Alan MacKenzie will become president of the company effective Sept. 1

European SEAC Opinion Unchanged: Microplastics Must Be Out Of All Cosmetics Within Six Years

The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.

QUOTED. 2 March 2021. Michael Coyle.

Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts